Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837330 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
A Phase 1 study, sponsored by Southeast Retina Center, Georgia.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00837330 is a Phase 1 study that has completed, run by Southeast Retina Center, Georgia. The registered enrollment target is 20 participants.
The verdict
NCT00837330, a Phase 1 study, has completed, sponsored by Southeast Retina Center, Georgia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of tiny, abnormal blood vessels under the retina. These abnormal blood vessels can bleed or leak fluid, causing disruption of normal retinal function and vision loss. Ranibizumab is a drug that is FDA-approved for the treatment of wet age-related macular degeneration (AMD) and is injected directly into the eye. Given the efficacy of ranibizumab in the treatment of wet AMD, and the postulated similarity between the disease mechanisms involved in both wet AMD and PCV, we believe ranibizumab will have a beneficial effect on visual function in patients with PCV.
Interventions
- DRUG ranibizumab 0.5 or 0.3 mg/0.05 cc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00837330
The ClinicalTrials.gov registry entry for NCT00837330 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southeast Retina Center, Georgia, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ranibizumab 0.5 or 0.3 mg/0.05 cc is the first listed.
NCT00837330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00837330 about?
NCT00837330 is a clinical study titled "Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy". This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of tiny, abnormal blood vessels under the retina. These abnormal blood ve...
What is the current status of trial NCT00837330?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-05. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00837330?
The interventions under investigation include: ranibizumab 0.5 or 0.3 mg/0.05 cc (DRUG).
Who is sponsoring clinical trial NCT00837330?
This trial is sponsored by Southeast Retina Center, Georgia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.